Npecia 5 Sai Michael Biotech
$29.70
Manufacturer: Sai Michael Biotech Substance: Finasteride (Propecia) Pack: 5mg (50 pills)
Additional information
| Manufacturer | |
|---|---|
| Package | |
| Substance |
Npecia 5 (Finasteride) is a medicament for the treatment of benign prostatic hyperplasia. The active ingredient is the pharmacological substance of the same name. Refers to inhibitors of the enzyme, called 5-alpha-reductase.
Pharmachologic effect
Finasteride is a 4-azasteroid compound that selectively and competitively inhibits 5α-reductase. This nicotinamide adenine dinucleotide phosphate (NADP) -dependent enzyme converts testosterone into dihydrotestosterone. The drug specifically inhibits the isoenzyme of 5α-reductase type 2, which leads to a significant decrease in the level of dihydrotestosterone in the prostate (> 90%) and in the circulatory system (from 60% to 80%).
Finasteride increases the level of testosterone prostate (approximately 85%) in patients with BPH, this does not affect the growth and morphology of the prostate. The drug has no pronounced affinity for androgen receptors. Finasteride significantly reduces plasma PSA levels by 41% – 71% in patients with BPH. However, the ratio of the values of unbound and total PSA levels does not affect the drug.
The size of the prostate gland is reduced by finasteride due to atrophy and apoptosis. The histological changes caused by the action of the drug were observed after 6 months from the beginning of the treatment. The glandular elements of the tissues of the prostate gland are most sensitive to finasteride. The drug reduces detrusor tone in patients with urinary retention caused by BPH.
Drug Interactions
There was no clinically significant interaction of finasteride with other drugs. With the combined use of finasteride with propranolol, digoxin, glibenclamide, warfarin, theophylline, angiotensin converting enzyme inhibitors, paracetamol, acetylsalicylic acid, alpha-adrenoblockers, beta adrenoblockers, calcium channel blockers, nitrates, diuretics, H2-histamine receptor blockers, HMG-CoA- Reductase inhibitors, nonsteroidal anti-inflammatory drugs, quinolones and benzodiazepines, there were no clinically significant manifestations of drug interaction.
